Showing results (501-510 of 529) with videos related to
Sort By:
Pageof 53
Journal of Lipid Research|January 18, 2005
High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteinsMatthias Schneider, Joseph L Witztum, Stephen G Young, et al.Thrombosis Research|September 10, 2014
Lupus anticoagulant and thrombosis in splenic marginal zone lymphomaJ Gebhart, K Lechner, C Skrabs, et al.Molecular Medicine (Cambridge, Mass.)|September 14, 2022
Variants influencing age at diagnosis of HNF1A-MODYAgnieszka H Ludwig-Słomczyńska, Michał T Seweryn, Piotr Radkowski, et al.Leukemia & Lymphoma|March 26, 2002
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-CW Hilbe, T Kühr, U Apfelbeck, et al.Journal of Hematology & Oncology|January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert PanelJ Caers, B Paiva, E Zamagni, et al.Leukemia|February 5, 2011
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statementM A Dimopoulos, A Palumbo, M Attal, et al.Leukemia|February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaM A Dimopoulos, X Leleu, A Palumbo, et al.Blood Cancer Journal|April 22, 2017
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatmentM A Dimopoulos, A K Stewart, T Masszi, et al.Journal of Internal Medicine|February 7, 2019
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial HypertensionS Bringhen, A Milan, M D'Agostino, et al.Leukemia Research|January 1, 1997
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II studyJ Thaler, W Hilbe, U Apfelbeck, et al.Pageof 53